Suppression of ser/thr phosphatase 4 (PP4C/PPP4C) mimics a novel post-mitotic action of fostriecin, producing mitotic slippage followed by tetraploid cell death

Molecular Cancer Research

Volumn 11, Issue 8, 2013, Pages 845-855

  Theobald, Benjamin ^a   Bonness, Kathy ^a   Musiyenko, Alla ^a   Andrews, Joel F ^a,b   Urban, Gudrun ^a   Huang, Xizhong ^a   Dean, Nicholas M ^c   Honkanen, Richard E ^a,b  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^c ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CASPASE 3; FOSTRIECIN; MEMBRANE PROTEIN; PHOSPHATASE; PP1C PROTEIN; PP2AC PROTEIN; PP5C PROTEIN; PPP4C PROTEIN; SERINE; THREONINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INHIBITION KINETICS; MITOSIS; MOLECULAR MECHANICS; PRIORITY JOURNAL; TETRAPLOIDY; TIME LAPSE IMAGING; TIME-LAPSE VIDEO MICROSCOPY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; DOSE-RESPONSE RELATIONSHIP, DRUG; HELA CELLS; HUMANS; MITOSIS; MOLECULAR MIMICRY; NUCLEAR PROTEINS; PHOSPHOPROTEIN PHOSPHATASES; POLYENES; PROTEIN PHOSPHATASE 1; PROTEIN PHOSPHATASE 2; PYRONES; TETRAPLOIDY;

EID: 84882759003     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0032     Document Type: Article

References (50)

1. Lewy DS, Gauss CM, Soenen DR, Boger DL. Fostriecin: chemistry and biology. Curr Med Chem 2002;9:2005-32.
2. Honkanen RE, Golden T. Regulators of serine/threonine protein phosphatases at the dawn of a clinical era? Curr Med Chem 2002;9: 2055-75.
3. Kawada M, Amemiya M, Ishizuka M, Takeuchi T. Differential induction of apoptosis in B16 melanoma and EL-4 lymphoma cells by cytostatin and bactobolin. Jpn J Cancer Res 1999;90:219-25.
4. Leopold WR, Shillis JL, Mertus AE, Nelson JM, Roberts BJ, Jackson RC. Anticancer activity of the structurally novel antibiotic Cl-920 and its analogues. Cancer Res 1984;44:1928-32.
5. de Jong RS, de Vries EG, Mulder NH. Fostriecin: a review of the preclinical data. Anticancer Drugs 1997;8:413-8.
6. Honkanen RE. Serine/threonine protein phosphatase inhibitors with anti tumor activity. Handbook of Exp Pharm 2005;167: 295-317.
7. Le LH, Erlichman C, Pillon L, Thiessen JJ, Day A, Wainman N, et al. Phase I and pharmacokinetic study of fostriecin given as an intravenous bolus daily for five consecutive days. Invest New Drugs 2004;22: 159-67.
8. de Jong RS, Mulder NH, Uges DR, Sleijfer DT, Höppener FJ, Groen HJ, et al. Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin. Br J Cancer 1999;79:882-7.
9. Susick RL Jr., Hawkins KL, Pegg DG. Preclinical toxicological evaluation of fostriecin, a novel anticancer antibiotic, in rats. Fundam Appl Toxicol 1990;15:258-69.
10. Walsh AH, Cheng A, Honkanen RE. Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A. FEBS Lett 1997;416:230-4.
11. Buck SB, Hardouin C, Ichikawa S, Soenen DR, Gauss CM, Hwang I, et al. Fundamental role of the fostriecin unsaturated lactone and implications for selective protein phosphatase inhibition. J Am Chem Soc 2003;125:15694-5.
12. Swingle MR, Amable L, Lawhorn BG, Buck SB, Burke CP, Ratti P, et al. Structure-Activity relationship studies of fostriecin, cytostatin, and key analogs, with PP1, PP2A, PP5, and (beta12-beta13)-chimeras (PP1/PP2A and PP5/PP2A), provide further insight into the inhibitory actions of fostriecin family inhibitors. J Pharmacol Exp Ther 2009;331:45-53.
13. Roberge M, Tudan C, Hung SM, Harder KW, Jirik FR, Anderson H. Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A. Cancer Res 1994;54:6115-21.
14. Kawada M, Amemiya M, Ishizuka M, Takeuchi T. Cytostatin, an inhibitor of cell adhesion to extracellular matrix, selectively inhibits protein phosphatase 2A. Biochim Biophys Acta 1999;1452:209-17.
15. Lawhorn BG, Boga SB, Wolkenberg SE, Colby DA, Gauss CM, Swingle MR, et al. Total synthesis and evaluation of cytostatin, its C10-C11 diastereomers, and additional key analogues: impact on PP2A inhibition. J Am Chem Soc 2006;128:16720-32.
16. Usui T, Marriott G, Inagaki M, Swarup G, Osada H. Protein phosphatase 2A inhibitors, phoslactomycins. Effects on the cytoskeleton in NIH/3T3 cells. J Biochem 1999;125:960-5.
17. Swingle M, Ni L, Honkanen RE. Small-molecule inhibitors of ser/thr protein phosphatases: specificity, use and common forms of abuse. Methods Mol Biol 2007;365:23-38.
18. Hastie CJ, Cohen PT. Purification of protein phosphatase 4 catalytic subunit: inhibition by the antitumour drug fostriecin and other tumour suppressors and promoters. FEBS Lett 1998;431:357-61.
19. Swingle MR, Honkanen RE, Ciszak EM. Structural basis for the catalytic activity of human serine/threonine protein phosphatase-5. J Biol Chem 2004;279:33992-9.
20. Takeuchi T, Takahashi N, Ishi K, Kusayanagi T, Kuramochi K, Sugawara F. Antitumor antibiotic fostriecin covalently binds to cysteine-269 residue of protein phosphatase 2A catalytic subunit in mammalian cells. Bioorg Med Chem 2009;17:8113-22.
21. Gao D, O'Doherty GA. Total synthesis of fostriecin: via a regio-And stereoselective polyene hydration, oxidation, and hydroboration sequence. Org Lett 2010;12:3752-5.
22. Hayashi Y, Yamaguchi H, Toyoshima M, Okado K, Toyo T, Shoji M. Formal total synthesis of fostriecin by 1,4-Asymmetric induction with an alkyne-cobalt complex. Chemistry 2010;16:10150-9.
23. Fry DW, Besserer JA, Boritzki TJ. Transport of the antitumor antibiotic Cl-920 into L1210 leukemia cells by the reduced folate carrier system. Cancer Res 1984;44:3366-70.
24. Spinella MJ, Brigle KE, Sierra EE, Goldman ID. Distinguishing between folate receptor-Alpha-mediated transport and reduced folate carriermediated transport in L1210 leukemia cells. J Biol Chem 1995;270: 7842-9.
25. Pillon L, Moore MJ, Thiessen JJ. Determination of fostriecin pharmacokinetics in plasma using high-pressure liquid chromatography assay. Ther Drug Monit 1994;16:186-90.
26. Hotz MA, Traganos F, Darzynkiewicz Z. Changes in nuclear chromatin related to apoptosis or necrosis induced by the DNA topoisomerase II inhibitor fostriecin in MOLT-4 and HL-60 cells are revealed by altered DNA sensitivity to denaturation. Exp Cell Res 1992;201:184-91.
27. Cheng A, Balczon R, Zuo Z, Koons JS, Walsh AH, Honkanen RE. Fostriecin-mediated G2-M-phase growth arrest correlates with abnormal centrosome replication, the formation of aberrant mitotic spindles, and the inhibition of serine/threonine protein phosphatase activity. Cancer Res 1998;58:3611-9.
28. Boritzki TJ, Wolfard TS, Besserer JA, Jackson RC, Fry DW. Inhibition of type II topoisomerase by fostriecin. Biochem Pharmacol 1988;37: 4063-8.
29. Bonness K, Aragon IV, Rutland B, Ofori-Acquah S, Dean NM, Honkanen RE. Cantharidin-induced mitotic arrest is associated with the formation of aberrant mitotic spindles and lagging chromosomes resulting, in part, from the suppression of PP2Aalpha. Mol Cancer Ther 2006;5:2727-36.
30. Zuo Z, Dean NM, Honkanen RE. Serine/threonine protein phosphatase type 5 acts upstream of p53 to regulate the induction of p21(WAF1/Cip1) and mediate growth arrest. J Biol Chem 1998;273:12250-8.
31. Cheng A, Dean NM, Honkanen RE. Serine/threonine protein phosphatase type 1gamma1 is required for the completion of cytokinesis in human A549 lung carcinoma cells. J Biol Chem 2000;275:1846-54.
32. Tang Z, Shu H, Qi W, Mahmood NA, Mumby MC, Yu H. PP2A is required for centromeric localization of Sgo1 and proper chromosome segregation. Dev Cell 2006;10:575-85.
33. Riedel CG, Katis VL, Katou Y, Mori S, Itoh T, Helmhart W, et al. Protein phosphatase 2A protects centromeric sister chromatid cohesion during meiosis I. Nature 2006;441:53-61.
34. Watanabe Y, Kitajima TS. Shugoshin protects cohesin complexes at centromeres. Philos Trans R Soc Lond B Biol Sci 2005;360:515-21, discussion 521.
35. Xu Z, Cetin B, Anger M, Cho US, Helmhart W, Nasmyth K, et al. Structure and function of the PP2A-shugoshin interaction. Mol Cell 2009;35:426-41.
36. Kanda T, Sullivan KF, Wahl GM. Histone-GFP fusion protein enables sensitive analysis of chromosome dynamics in living mammalian cells. Curr Biol 1998;8:377-85.
37. Dean NM, Griffey RH. Identification and characterization of secondgeneration antisense oligonucleotides. Antisense Nucleic Acid Drug Dev 1997;7:229-33.
38. Urban G, Golden T, Aragon IV, Cowsert L, Cooper SR, Dean NM, et al. Identification of a functional link for the p53 tumor suppressor protein in dexamethasone-induced growth suppression. J Biol Chem 2003;278: 9747-53.
39. Huang X, Cheng A, Honkanen RE. Genomic organization of the human PP4 gene encoding a serine/threonine protein phosphatase (PP4) suggests a common ancestry with PP2A. Genomics 1997;44: 336-43.
40. Zuo Z, Urban G, Scammell JG, Dean NM, McLean TK, Aragon I, et al. Ser/Thr protein phosphatase type 5 (PP5) is a negative regulator of glucocorticoid receptor-mediated growth arrest. Biochemistry 1999; 38:8849-57.
41. Kloeker S, Reed R, McConnell JL, Chang D, Tran K, Westphal RS, et al. Parallel purification of three catalytic subunits of the protein serine/threonine phosphatase 2A family (PP2A(C), PP4(C), and PP6(C)) and analysis of the interaction of PP2A(C) with alpha4 protein. Protein Expr Purif 2003;31:19-33.
42. Forester CM, Maddox J, Louis JV, Goris J, Virshup DM. Control of mitotic exit by PP2A regulation of Cdc25C and Cdk1. Proc Natl Acad Sci U S A 2007;104:19867-72.
43. Burgess A, Vigneron S, Brioudes E, Labbe JC, Lorca T, Castro A. Loss of human Greatwall results in G2 arrest and multiple mitotic defects due to deregulation of the cyclin B-Cdc2/PP2A balance. Proc Natl Acad Sci U S A 2010;107:12564-9.
44. Honkanen RE. Serine threonine protein phosphatases. In: Antisense drug technology: principles, strategies, and applications. Crooke S.T., editor. New York: Marcel Dekker, Inc.; 2001. p. 587-614.
45. Chowdhury D, Xu X, Zhong X, Ahmed F, Zhong J, Liao J, et al. A PP4-phosphatase complex dephosphorylates gamma-H2AX generated during DNA replication. Mol Cell 2008;31:33-46.
46. Sousa-Nunes R, Chia W, Somers WG. Protein phosphatase 4 mediates localization of the Miranda complex during Drosophila neuroblast asymmetric divisions. Genes Dev 2009;23:359-72.
47. Toyo-oka K, Mori D, Yano Y, Shiota M, Iwao H, Goto H, et al. Protein phosphatase 4 catalytic subunit regulates Cdk1 activity and microtubule organization via NDEL1 dephosphorylation. J Cell Biol 2008;180: 1133-47.
48. Ou Y, Rattner JB. The centrosome in higher organisms: structure, composition, and duplication. Int Rev Cytol 2004;238:119-82.
49. Steigemann P, Wurzenberger C, Schmitz MH, Held M, Guizetti J, Maar S, et al. Aurora B-mediated abscission checkpoint protects against tetraploidization. Cell 2009;136:473-84.
50. Lera RF, Burkard ME. High mitotic activity of Polo-like kinase 1 is required for chromosome segregation and genomic integrity in human epithelial cells. J Biol Chem 287:42812-25.